Myriad Genetics (NASDAQ:MYGN) & ProQR Therapeutics (NASDAQ:PRQR) Head-To-Head Survey

ProQR Therapeutics (NASDAQ:PRQR) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and target prices for ProQR Therapeutics and Myriad Genetics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1	1	7	0	2.67
Myriad Genetics	3	6	4	0	2.08

ProQR Therapeutics currently has a consensus target price of $7.14, indicating a potential upside of 376.19%. Myriad Genetics has a consensus target price of $9.44, indicating a potential upside of 84.46%. Given ProQR Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe ProQR Therapeutics is more favorable than Myriad Genetics.

Earnings and Valuation

This table compares ProQR Therapeutics and Myriad Genetics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$20.46 million	7.71	-$30.04 million	($0.47)	-3.19
Myriad Genetics	$825.30 million	0.58	-$127.30 million	($4.33)	-1.18

ProQR Therapeutics has higher earnings, but lower revenue than Myriad Genetics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Comparatively, 2.4% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

ProQR Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.

Profitability

This table compares ProQR Therapeutics and Myriad Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-273.20%	-58.70%	-29.37%
Myriad Genetics	-48.53%	-7.11%	-4.48%

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

About Myriad Genetics

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.